<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p70" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_70{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_70{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_70{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_70{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_70{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_70{left:238px;bottom:1022px;letter-spacing:-0.01px;}
#t7_70{left:238px;bottom:988px;letter-spacing:-0.01px;}
#t8_70{left:238px;bottom:968px;letter-spacing:-0.01px;}
#t9_70{left:238px;bottom:949px;letter-spacing:-0.01px;}
#ta_70{left:238px;bottom:929px;letter-spacing:-0.01px;}
#tb_70{left:238px;bottom:910px;letter-spacing:-0.01px;}
#tc_70{left:238px;bottom:890px;letter-spacing:-0.01px;}
#td_70{left:238px;bottom:871px;letter-spacing:-0.01px;}
#te_70{left:238px;bottom:851px;letter-spacing:-0.01px;}
#tf_70{left:238px;bottom:832px;letter-spacing:-0.01px;}
#tg_70{left:238px;bottom:813px;letter-spacing:-0.01px;}
#th_70{left:238px;bottom:793px;letter-spacing:-0.01px;}
#ti_70{left:238px;bottom:774px;letter-spacing:-0.01px;}
#tj_70{left:238px;bottom:754px;letter-spacing:-0.01px;}
#tk_70{left:238px;bottom:735px;letter-spacing:-0.01px;}
#tl_70{left:238px;bottom:642px;letter-spacing:-0.01px;}
#tm_70{left:238px;bottom:607px;letter-spacing:-0.01px;}
#tn_70{left:238px;bottom:588px;letter-spacing:-0.01px;}
#to_70{left:238px;bottom:568px;letter-spacing:-0.01px;}
#tp_70{left:238px;bottom:549px;letter-spacing:-0.01px;}
#tq_70{left:238px;bottom:529px;letter-spacing:-0.01px;}
#tr_70{left:238px;bottom:510px;letter-spacing:-0.01px;}
#ts_70{left:238px;bottom:490px;letter-spacing:-0.01px;}
#tt_70{left:238px;bottom:471px;letter-spacing:-0.01px;}
#tu_70{left:238px;bottom:452px;letter-spacing:-0.01px;}
#tv_70{left:238px;bottom:432px;letter-spacing:-0.01px;}
#tw_70{left:238px;bottom:413px;letter-spacing:-0.01px;}
#tx_70{left:238px;bottom:393px;letter-spacing:-0.01px;}
#ty_70{left:238px;bottom:374px;letter-spacing:-0.01px;}
#tz_70{left:238px;bottom:354px;letter-spacing:-0.01px;}
#t10_70{left:238px;bottom:281px;letter-spacing:-0.01px;}
#t11_70{left:238px;bottom:261px;letter-spacing:-0.01px;}
#t12_70{left:238px;bottom:242px;letter-spacing:-0.01px;}
#t13_70{left:238px;bottom:223px;letter-spacing:-0.01px;}
#t14_70{left:238px;bottom:203px;letter-spacing:-0.01px;}
#t15_70{left:238px;bottom:184px;letter-spacing:-0.01px;}
#t16_70{left:238px;bottom:164px;letter-spacing:-0.01px;}
#t17_70{left:238px;bottom:145px;letter-spacing:-0.01px;}
#t18_70{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_70{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_70{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_70{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts70" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg70Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg70" style="-webkit-user-select: none;"><object width="908" height="1286" data="70/70.svg" type="image/svg+xml" id="pdf70" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_70" class="t s0_70">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_70" class="t s1_70">70 </span>
<span id="t3_70" class="t s2_70">In the previously described RTOG study [187, 188], approximately 15% of patients were affected </span>
<span id="t4_70" class="t s2_70">by late pharyngeal/esophageal and another 15% by late laryngeal grade III/IV adverse events. </span>
<span id="t5_70" class="t s2_70">However, no late functional assessment was performed in this study. </span>
<span id="t6_70" class="t s2_70">Background 7.32. </span>
<span id="t7_70" class="t s2_70">Since there are no adequate randomized clinical trials directly comparing primary </span>
<span id="t8_70" class="t s2_70">chemoradiotherapy versus surgery plus adjuvant radiotherapy or chemoradiotherapy, and </span>
<span id="t9_70" class="t s2_70">none are expected in the near future, it is not possible to make a clear scientific decision as to </span>
<span id="ta_70" class="t s2_70">which patients benefit most from which procedure. American registry studies show that T4a </span>
<span id="tb_70" class="t s2_70">laryngeal carcinomas have significantly worse survival rates after chemoradiotherapy </span>
<span id="tc_70" class="t s2_70">compared to primary laryngectomy [225]. However, patients who received primary </span>
<span id="td_70" class="t s2_70">chemoradiotherapy had significantly higher N categories than those who were primarily </span>
<span id="te_70" class="t s2_70">treated surgically. Although the authors used propensity adjustments to compensate for this </span>
<span id="tf_70" class="t s2_70">bias in the multivariate analysis as far as possible, the disadvantage for chemoradiotherapy </span>
<span id="tg_70" class="t s2_70">remained statistically significant, so that patients with T4a tumors, especially those with a high </span>
<span id="th_70" class="t s2_70">tumor burden, may not be the optimal candidates for larynx preservation using </span>
<span id="ti_70" class="t s2_70">chemoradiotherapy. The tumors currently considered ideal for larynx preservation are, without </span>
<span id="tj_70" class="t s2_70">further consideration of tumor biological peculiarities, the larger T3 carcinomas that can no </span>
<span id="tk_70" class="t s2_70">longer be treated by partial resection [226, 227], thus a selected group. </span>
<span id="tl_70" class="t s2_70">Background 7.33 and 7.34. </span>
<span id="tm_70" class="t s2_70">If functional preservation of the larynx is sought by means of induction chemotherapy, a </span>
<span id="tn_70" class="t s2_70">taxane-containing chemotherapy protocol has proven to be advantageous [228, 229]. With high </span>
<span id="to_70" class="t s2_70">response rates and good selection options, only a few salvage operations are usually necessary. </span>
<span id="tp_70" class="t s2_70">This effect was also confirmed in the DeLOS-II study, although without any additive value of </span>
<span id="tq_70" class="t s2_70">cetuximab for induction for organ preservation and overall survival. In approximately one third </span>
<span id="tr_70" class="t s2_70">of cases after a lack of response to the short induction (1 cycle of TPF/TP and subsequent </span>
<span id="ts_70" class="t s2_70">endoscopic </span>
<span id="tt_70" class="t s2_70">Response assessment) an early laryngectomy was performed before radiation, which led to </span>
<span id="tu_70" class="t s2_70">comparatively low toxicities/complications and a very good 2-year survival rate [198]. Induction </span>
<span id="tv_70" class="t s2_70">therapies are also being modified to use less toxic substances, and 5-FU is being partially </span>
<span id="tw_70" class="t s2_70">replaced. A randomized phase II study showed that cetuximab administered simultaneously </span>
<span id="tx_70" class="t s2_70">with subsequent radiation therapy can achieve equally good results as simultaneous </span>
<span id="ty_70" class="t s2_70">administration of cisplatin, with a different toxicity profile (greater cutaneous toxicity, less </span>
<span id="tz_70" class="t s2_70">hemato- and nephrotoxicity), which may be beneficial for some patients [196]. </span>
<span id="t10_70" class="t s2_70">There is still disagreement among experts as to whether multimodal therapy concepts for </span>
<span id="t11_70" class="t s2_70">laryngeal organ preservation should be considered as a standard therapy as an alternative to </span>
<span id="t12_70" class="t s2_70">laryngectomy or whether they should continue to be carried out primarily in studies. Critics </span>
<span id="t13_70" class="t s2_70">cite the high late toxicity that limits function, the higher non-tumor-related mortality and the </span>
<span id="t14_70" class="t s2_70">comparatively high complication rates if salvage surgery is necessary. Proponents, on the </span>
<span id="t15_70" class="t s2_70">other hand, cite the high rate of organ preservation with adequate patient selection, the </span>
<span id="t16_70" class="t s2_70">possibility of salvage surgery as a curative option and the lack of a survival disadvantage. </span>
<span id="t17_70" class="t s2_70">Careful individual advice for the patient is therefore of particular importance in this situation. </span>
<span id="t18_70" class="t s0_70">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
